Common Cold  - Market Insights, Epidemiology and Market Forecast-2028

Common Cold - Market Insights, Epidemiology and Market Forecast-2028

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 7-10 business days
  • Publication: Feb, 2019
  • SKU: DIMI0404
  • Single User License
    ()
    $6,250.00
  • Site License
    ()
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's “Common Cold - Market Insights, Epidemiology and Market Forecast – 2028” report provides  the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.
Markets Covered

  •  United States
  •  EU5 (Germany, France, Italy, Spain and the United Kingdom)
  •  Japan

Study Period: 2017-2028
Common Cold Understanding and Treatment Algorithm
The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Common Cold in the US, Europe, and Japan are also provided in the report.
Common Cold Epidemiology
This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.
Common Cold Product Profiles & Analysis
This part of the Common Cold report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals,  patent details and other major breakthroughs.
Common Cold Market Outlook
The Common Cold market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.
Common Cold Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.
Common Cold Report Insights

  •  Patient Population in Common Cold
  •  Therapeutic Approaches in Common Cold
  •  Common Cold Pipeline Analysis
  •  Common Cold Market Size and Trends
  •  Common Cold Market Opportunities
  •  Impact of upcoming Therapies in Common Cold

Common Cold Report Key Strengths

  •  10 Year Forecast
  •  7MM Coverage
  •  Epidemiology Segmentation
  •  Drugs Uptake
  •  Highly Analyzed Market
  •  Key Cross Competition

Common Cold Report Assessment

  •  Current Treatment Practices in Common Cold
  •  Unmet Needs in Common Cold
  •  Detailed Common Cold Pipeline Product Profiles
  •  Market Attractiveness
  •  Market Drivers and Barriers

Key Benefits

  •  This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Common Cold market
  •  Organize sales and marketing efforts by identifying the best opportunities for Common Cold market
  •  To understand the future market competition in the Common Cold market.
  •  Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages 
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Common Cold: 7MM Market Analysis
12.1. 7MM Market Size of Common Cold
12.2. 7MM Percentage Share of drugs marketed for Common Cold
12.3. 7MM Market Sales of Common Cold by Products
13. Common Cold: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Common Cold in United States
13.1.2. Percentage Share of drugs marketed for Common Cold in United States
13.1.3. Market Sales of Common Cold by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Common Cold in Germany
13.2.1.2. Percentage Share of drugs marketed for Common Cold in Germany
13.2.1.3. Market Sales of Common Cold by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Common Cold in France
13.2.2.2. Percentage Share of drugs marketed for Common Cold in France
13.2.2.3. Market Sales of Common Cold by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Common Cold in Italy
13.2.3.2. Percentage Share of drugs marketed for Common Cold in Italy
13.2.3.3. Market Sales of Common Cold by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Common Cold in Spain
13.2.4.2. Percentage Share of drugs marketed for Common Cold in Spain
13.2.4.3. Market Sales of Common Cold by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Common Cold in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Common Cold in United Kingdom
13.2.5.3. Market Sales of Common Cold by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Common Cold in Japan
13.3.2. Percentage Share of drugs marketed for Common Cold in Japan
13.3.3. Market Sales of Common Cold by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

1. Report Introduction
2. Common Cold Market Overview at a Glance
2.1. Market Share Distribution of Common Cold in 2018
2.2. Market Share Distribution of Common Cold in 2028
3. Disease Background and Overview: Common Cold
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Common Cold in 7MM
4.3. Total Prevalent  Patient Population of Common Cold in 7MM – By Countries
5. Epidemiology of Common Cold by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Common Cold
5.1.3. Sub-Type Specific cases of the Common Cold *Indication Specific
5.1.4. Sex- Specific Cases of the Common Cold*Indication Specific
5.1.5. Diagnosed Cases of the Common Cold
5.1.6. Treatable Cases of the Common Cold
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Common Cold
5.4.3. Sub-Type Specific cases of the Common Cold*

5.4.4. Sex- Specific Cases of the Common Cold*

5.4.5. Diagnosed Cases of the Common Cold
5.4.6. Treatable Cases of the Common Cold
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Common Cold
5.5.3. Sub-Type Specific cases of the Common Cold*

5.5.4. Sex- Specific Cases of the Common Cold*

5.5.5. Diagnosed Cases of the Common Cold
5.5.6. Treatable Cases of the Common Cold
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Common Cold
5.6.3. Sub-Type Specific cases of the Common Cold*

5.6.4. Sex- Specific Cases of the Common Cold*

5.6.5. Diagnosed Cases of the Common Cold
5.6.6. Treatable Cases of the Common Cold
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Common Cold
5.7.3. Sub-Type Specific cases of the Common Cold*

5.7.4. Sex- Specific Cases of the Common Cold*

5.7.5. Diagnosed Cases of the Common Cold
5.7.6. Treatable Cases of the Common Cold
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Common Cold
5.8.3. Sub-Type Specific cases of the Common Cold*

5.8.4. Sex- Specific Cases of the Common Cold*

5.8.5. Diagnosed Cases of the Common Cold
5.8.6. Treatable Cases of the Common Cold
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Common Cold
5.9.3. Sub-Type Specific cases of the Common Cold*

5.9.4. Sex- Specific Cases of the Common Cold*

5.9.5. Diagnosed Cases of the Common Cold
5.9.6. Treatable Cases of the Common Cold
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Common Cold
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Common Cold
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages 
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Deta